Amy Qin

TL;DR: An open-label phase 1b and randomised phase 2 study of doxorubicin plus olaratumab treatment in patients with unresectable or metastatic soft-tissue sarcoma at 16 clinical sites in the USA, finding progression-free survival in phase 2 was 6.6 months and the efficacy was assessed.

TL;DR: LY3022856 was well tolerated up to a dose of 30 mg/kg qwk, but with minimal anti-tumor activity in CRC, which is primarily mediated by the vascular endothelial growth factor receptor 3 (VEGFR-3).

TL;DR: Olaratumab was well tolerated and showed preliminary antitumor activity in patients with advanced solid tumors, and the concentration found to be efficacious in preclinical xenograft models was higher than 155 μg/mL; the MTD was not identified with the doses studied.

TL;DR: A pooled analysis of nine phase I and II trastuzumab deruxtecan (T-DXd) monotherapy studies described drug-related interstitial lung disease (ILD)/pneumonitis in patients treated with T-DXD as discussed by the authors .

TL;DR: While there was no apparent effect on PFS in patients without PDGFRα mutations, patients with PDG FRα-mutant GIST treated with olaratumab had longer disease control compared with historical data for this genotype.